Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar 1;27(5):1580.
doi: 10.1158/1078-0432.CCR-20-2698.

Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter

Zhiqiang Xue #  1 , Xueguang Guo #  2 , Jiaxin Wen  3 , Wenhan Cai  3 , Xinying Xue  4 , Xiaochen Zhao  5 , Jing Zhao  5 , Yuezong Bai  5
Affiliations
Comment

Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter

Zhiqiang Xue et al. Clin Cancer Res. .
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Aggarwal C, Thompson JC, Chien AL, Quinn KJ, Hwang W-T, Black TA, et al. Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer. Clin Cancer Res. 2020;26:2354–61.
    1. Biton J, Mansuet-Lupo A, Pecuchet N, Alifano M, Ouakrim H, Arrondeau J, et al. TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma. Clin Cancer Res. 2018;24:5710–23.
    1. Guibert N, Jones G, Beeler JF, Plagnol V, Morris C, Mourlanette J, et al. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2019;137:1–6.
    1. Wang Z, Duan J, Wang G, Zhao J, Xu J, Han J, et al. Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for patients with NSCLC treated with PD-(L)1 inhibitors. J Thorac Oncol. 2020;15:556–67.
    1. Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24:1441–8.

Substances

LinkOut - more resources